LT5058B - Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui - Google Patents

Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui Download PDF

Info

Publication number
LT5058B
LT5058B LT2002063A LT2002063A LT5058B LT 5058 B LT5058 B LT 5058B LT 2002063 A LT2002063 A LT 2002063A LT 2002063 A LT2002063 A LT 2002063A LT 5058 B LT5058 B LT 5058B
Authority
LT
Lithuania
Prior art keywords
metformin
glyburide
dose
combination
low
Prior art date
Application number
LT2002063A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002063A (en
Inventor
Beth Anne Piper
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2002063A publication Critical patent/LT2002063A/xx
Publication of LT5058B publication Critical patent/LT5058B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
LT2002063A 1999-11-03 2002-05-24 Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui LT5058B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (2)

Publication Number Publication Date
LT2002063A LT2002063A (en) 2003-06-25
LT5058B true LT5058B (lt) 2003-09-25

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002063A LT5058B (lt) 1999-11-03 2002-05-24 Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui

Country Status (23)

Country Link
EP (1) EP1229918B1 (ru)
JP (1) JP5183844B2 (ru)
KR (1) KR20070089259A (ru)
CN (1) CN1450902A (ru)
AR (1) AR026356A1 (ru)
AT (1) ATE390140T1 (ru)
AU (1) AU780106B2 (ru)
BR (1) BR0015294A (ru)
CA (1) CA2389928C (ru)
EE (1) EE05260B1 (ru)
HU (1) HU229352B1 (ru)
IL (1) IL149139A0 (ru)
LT (1) LT5058B (ru)
LV (1) LV12910B (ru)
MX (1) MXPA02004282A (ru)
NO (1) NO330026B1 (ru)
NZ (1) NZ518278A (ru)
PL (1) PL199278B1 (ru)
RU (1) RU2275915C2 (ru)
SK (1) SK287810B6 (ru)
TW (1) TWI280125B (ru)
UY (1) UY26424A1 (ru)
WO (1) WO2001032157A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
CN101897970A (zh) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
DK2200606T3 (en) 2007-09-10 2017-12-04 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US20120115799A1 (en) 2010-05-11 2012-05-10 Wenhua Wang Pharmaceutical formulations
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
CA2825162A1 (en) * 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
EP0749751A2 (en) 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
US5631224A (en) 1992-03-19 1997-05-20 Novo Nordisk A/S Use of a peptide
WO1997017975A1 (en) 1995-11-14 1997-05-22 Abiogen Pharma S.R.L. A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
EP0974356A1 (en) 1998-07-15 2000-01-26 Lipha Tablets comprising a combination of metformin and glibenclamide
US9353141B2 (en) 2012-01-25 2016-05-31 Galecto Biotech Ab Galectoside inhibitors of galectins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US5631224A (en) 1992-03-19 1997-05-20 Novo Nordisk A/S Use of a peptide
EP0749751A2 (en) 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes
WO1997017975A1 (en) 1995-11-14 1997-05-22 Abiogen Pharma S.R.L. A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
EP0974356A1 (en) 1998-07-15 2000-01-26 Lipha Tablets comprising a combination of metformin and glibenclamide
US9353141B2 (en) 2012-01-25 2016-05-31 Galecto Biotech Ab Galectoside inhibitors of galectins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CROUSE ET AL.: "Effects of combination of glipizide/metformin treatment on oxidizability of LLD in NIDDIM", CIRCULATION, 1996, pages 1508
EDWARDS ET AL.: "Combination of glipizide/metformin treatment reduces low density lipoprotein binding to arterial proteoglycans in DIDDM", DIABETES, 1997, pages 46
HIGINBOTHAM ET AL.: "Dauble-Blind Trial of Metformin in the Therapy of Non-Ketotic Diadetes", THE MED. JOURNAL OF AUSTRALIA, 1979, pages 154 - 156
VIGNERI ET AL.: "Treatment of NIDDM Patients with Secondary Failure to Glyburide", DIABETE & METABOLISME, 1991, pages 232 - 234, XP000570538

Also Published As

Publication number Publication date
JP5183844B2 (ja) 2013-04-17
JP2003519621A (ja) 2003-06-24
MXPA02004282A (es) 2003-02-17
KR20070089259A (ko) 2007-08-30
WO2001032157A3 (en) 2002-01-24
EE05260B1 (et) 2010-02-15
HUP0300218A2 (hu) 2003-06-28
NO330026B1 (no) 2011-02-07
PL199278B1 (pl) 2008-09-30
NO20022087L (no) 2002-06-24
AU1082601A (en) 2001-05-14
SK287810B6 (sk) 2011-10-04
LV12910B (en) 2003-05-20
AU780106B2 (en) 2005-03-03
CA2389928C (en) 2010-03-23
LT2002063A (en) 2003-06-25
CA2389928A1 (en) 2001-05-10
WO2001032157A2 (en) 2001-05-10
RU2002114820A (ru) 2004-03-10
NO20022087D0 (no) 2002-05-02
EP1229918A2 (en) 2002-08-14
CN1450902A (zh) 2003-10-22
EE200200242A (et) 2003-12-15
AR026356A1 (es) 2003-02-05
IL149139A0 (en) 2002-11-10
EP1229918B1 (en) 2008-03-26
HUP0300218A3 (en) 2006-02-28
UY26424A1 (es) 2001-05-31
NZ518278A (en) 2004-10-29
ATE390140T1 (de) 2008-04-15
RU2275915C2 (ru) 2006-05-10
HU229352B1 (en) 2013-11-28
BR0015294A (pt) 2003-07-15
TWI280125B (en) 2007-05-01
SK5002002A3 (en) 2004-05-04
PL364885A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
US7598262B2 (en) Method for treating diabetes
LT5058B (lt) Mažos dozės metformino ir gliburido deriniai, skirti diabeto gydymui
US7507768B2 (en) Antidiabetic formulation and method
JP2003519621A5 (ru)
AU8022900B2 (ru)

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20201013